Tower Research Capital (TRC)’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Tower Research Capital (TRC)’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-59	Closed	–	–	4832
2019 Q3	$0	Buy	+59	New	+$213	﹤0.01%	4802
2019 Q2	–	Sell	-5,303	Closed	-$19K	–	4669
2019 Q1	$19K	Buy	5,303 +4,460	+529%	+$24.2K	﹤0.01%	2311
2018 Q4	$3K	Buy	843 +350	+71%	+$4.47K	﹤0.01%	3282
2018 Q3	$10K	Sell	493 -380	-44%	-$9.61K	﹤0.01%	2803
2018 Q2	$28K	Buy	873 +13	+2%	+$468	﹤0.01%	2223
2018 Q1	$32K	Buy	860 +740	+617%	+$48.7K	﹤0.01%	1944
2017 Q4	$9K	Buy	+120	New	+$8.88K	﹤0.01%	2648

Other funds holding MLNT

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCM

Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Tower Research Capital (TRC)'s MLNT Position: Q4 2019 in Review

Tower Research Capital (TRC) sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2019, closing a stake of 59 shares.

Tower Research Capital (TRC) first reported a position in MLNT in Q4 2017 and held it in 7 quarters. The position peaked at $32K in Q1 2018. 37 funds tracked by Wall St. Rank hold MLNT as of Q4 2019.

Tower Research Capital (TRC) reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Tower Research Capital (TRC) sold 59 Melinta Therapeutics, Inc. Common Stock shares in Q4 2019.
Tower Research Capital (TRC) first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
Tower Research Capital (TRC)'s Melinta Therapeutics, Inc. Common Stock position peaked at $32K in Q1 2018.
37 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2019, filed 7 Feb 2020.